Evidence map›Paper›PMID 27532816›Full record

ArticleCurrent protocols in stem cell biology2016

Efficient Generation of Viral and Integration-Free Human Induced Pluripotent Stem Cell-Derived Oligodendrocytes.

Araceli Espinosa-Jeffrey, Bruno Blanchi, Juan Carlos Biancotti, Shalini Kumar, Megumi Hirose, Berhan Mandefro, Dodanim Talavera-Adame, Nissim Benvenisty, Jean de Vellis

Abstract read
In one paragraph

Article in Current protocols in stem cell biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. In memory of Jean de Vellis (1935-2018).Journal of neurodevelopmental disorders · 2019
    Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Araceli Espinosa-JeffreyIntellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience, David Geffen School of Medicine at UCLA, Los Angeles, California.
Bruno BlanchiIntellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience, David Geffen School of Medicine at UCLA, Los Angeles, California.
Juan Carlos BiancottiZilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.
Shalini KumarIntellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience, David Geffen School of Medicine at UCLA, Los Angeles, California.
Megumi HiroseIntellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience, David Geffen School of Medicine at UCLA, Los Angeles, California.
Berhan MandefroRegenerative Medicine Institute, Cedars Sinai Medical Center, Los Angeles, California.
Dodanim Talavera-AdameRegenerative Medicine Institute, Cedars Sinai Medical Center, Los Angeles, California.
Nissim BenvenistyInstitute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Jean de VellisIntellectual and Developmental Disabilities Research Center, Semel Institute for Neuroscience, David Geffen School of Medicine at UCLA, Los Angeles, California.

Funding

Stem CellsP30HD004612 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOOKHEIMER, SUSAN Y · 1985 to 2014
$19.5M
VIP AND PACP ACTION IN CNS DEVELOPMENT AND INJURYP01HD006576 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DE VELLIS, JEAN · 1985 to 2006
$7.8M
UCLA Center for Translational Research in Neurodevelopment: UC-TRaNU54HD087101 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCCRACKEN, JAMES T. · 2016 to 2020
$6.5M
NICHD NIH HHS P01 HD006576NICHD NIH HHS P30 HD004612NICHD NIH HHS U54 HD087101
6 · The paper itself

Abstract

Here we document three highly reproducible protocols: (1) a culture system for the derivation of human oligodendrocytes (OLs) from human induced pluripotent stem cells (hiPS) and their further maturation-our protocol generates viral- and integration-free OLs that efficiently commit and move forward in the OL lineage, recapitulating all the steps known to occur during in vivo development; (2) a method for the isolation, propagation and maintenance of neural stem cells (NSCs); and (3) a protocol for the production, isolation, and maintenance of OLs from perinatal rodent and human brain-derived NSCs. Our unique culture systems rely on a series of chemically defined media, specifically designed and carefully characterized for each developmental stage of OL as they advance from OL progenitors to mature, myelinating cells. We are confident that these protocols bring our field a step closer to efficient autologous cell replacement therapies and disease modeling. © 2016 by John Wiley & Sons, Inc.

Indexed as

AnimalsAnimals, NewbornBrainCell Culture TechniquesCell DifferentiationCell LineageCell SurvivalClone CellsEctodermEmbryoid BodiesFetusFreezingHumansInduced Pluripotent Stem CellsNeural Stem CellsNeuronschemically defined mediahuman induced pluripotent stem cellslineage progressionneural stem cellsneurospheresNSColigodendrocyte maturationoligodendrocyte specificationoligospheres

Identifiers

PMID27532816
PMCPMC5087818

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.